Early test of cancer Drug's immune effects halted
NCT ID NCT04630353
Summary
This early study aimed to see how a single dose of an experimental drug called HB-201 affects the immune system in people with HPV 16+ head/neck or cervical cancer. It was given to 10 participants in the short window between their cancer diagnosis and their scheduled surgery or chemoradiation treatment. The main goal was to measure immune responses in the blood and tumor tissue, not to treat the cancer itself. The trial was terminated early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HPV 16+ CONFIRMED OROPHARYNX CANCER AND CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin, 53226, United States
Conditions
Explore the condition pages connected to this study.